316 related articles for article (PubMed ID: 19841536)
1. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation.
Bornstein S; White R; Malkoski S; Oka M; Han G; Cleaver T; Reh D; Andersen P; Gross N; Olson S; Deng C; Lu SL; Wang XJ
J Clin Invest; 2009 Nov; 119(11):3408-19. PubMed ID: 19841536
[TBL] [Abstract][Full Text] [Related]
2. Smad4: gatekeeper gene in head and neck squamous cell carcinoma.
Korc M
J Clin Invest; 2009 Nov; 119(11):3208-11. PubMed ID: 19841540
[TBL] [Abstract][Full Text] [Related]
3. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Qiu W; Schönleben F; Li X; Su GH
Cancer Lett; 2007 Jan; 245(1-2):163-70. PubMed ID: 16478646
[TBL] [Abstract][Full Text] [Related]
4. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
5. Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.
Hernandez AL; Wang Y; Somerset HL; Keysar SB; Aisner DL; Marshall C; Bowles DW; Karam SD; Raben D; Jimeno A; Varella-Garcia M; Wang XJ
Mol Carcinog; 2019 May; 58(5):666-673. PubMed ID: 30575147
[TBL] [Abstract][Full Text] [Related]
6. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma.
Tyagi A; Gu M; Takahata T; Frederick B; Agarwal C; Siriwardana S; Agarwal R; Sclafani RA
Clin Cancer Res; 2011 Aug; 17(16):5402-11. PubMed ID: 21705453
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-β1 tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4.
Park Y; Kim W; Lee JM; Park J; Cho JK; Pang K; Lee J; Kim D; Park SW; Yang KM; Kim SJ
Oncogene; 2015 Sep; 34(39):5037-45. PubMed ID: 25531329
[TBL] [Abstract][Full Text] [Related]
10. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
Báez A; Cantor A; Fonseca S; Marcos-Martinez M; Mathews LA; Muro-Cacho CA; Muñoz-Antonia T
Clin Cancer Res; 2005 May; 11(9):3191-7. PubMed ID: 15867212
[TBL] [Abstract][Full Text] [Related]
11. Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer.
Stoepker C; Ameziane N; van der Lelij P; Kooi IE; Oostra AB; Rooimans MA; van Mil SE; Brink A; Dietrich R; Balk JA; Ylstra B; Joenje H; Feller SM; Brakenhoff RH
Cancer Res; 2015 Sep; 75(17):3543-53. PubMed ID: 26122845
[TBL] [Abstract][Full Text] [Related]
12. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
13. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
Ozawa H; Ranaweera RS; Izumchenko E; Makarev E; Zhavoronkov A; Fertig EJ; Howard JD; Markovic A; Bedi A; Ravi R; Perez J; Le QT; Kong CS; Jordan RC; Wang H; Kang H; Quon H; Sidransky D; Chung CH
Clin Cancer Res; 2017 Sep; 23(17):5162-5175. PubMed ID: 28522603
[No Abstract] [Full Text] [Related]
14. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
16. Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling.
Romick-Rosendale LE; Hoskins EE; Privette Vinnedge LM; Foglesong GD; Brusadelli MG; Potter SS; Komurov K; Brugmann SA; Lambert PF; Kimple RJ; Virts EL; Hanenberg H; Gillison ML; Wells SI
Clin Cancer Res; 2016 Apr; 22(8):2062-73. PubMed ID: 26603260
[TBL] [Abstract][Full Text] [Related]
17. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
18. Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma.
Lei Y; Lui VW; Grandis JR; Egloff AM
PLoS One; 2014; 9(1):e85619. PubMed ID: 24465623
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.
Türke C; Horn S; Petto C; Labudde D; Lauer G; Wittenburg G
Int J Oncol; 2017 Jun; 50(6):2207-2220. PubMed ID: 28440438
[TBL] [Abstract][Full Text] [Related]
20. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
